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low-density lipoprotein (LDL) cholesterol and subsequently lead
to cardiovascular events. OBJECTIVE: To examine the associa-
tion of variable patient compliance with statins to the control of
serum LDL. METHODS: A 6-month prospective observational
cohort study was conducted at the outpatient clinics of a public
teaching hospital in Hong Kong. Patients with a 10-year risk for
CHD > 20% or CHD risk equivalents who had been initiated
on statin monotherapy for < 12 months were recruited. The
statin prescription was dispensed to study patients in a bottle
with the Medication Event Monitoring System (MEMS) to
record the date and time the bottle cap was removed and
replaced. Lipid proﬁles were obtained at baseline and two
follow-up visits at month 3 and month 6. RESULTS: A total of
82 patients were recruited and 60.1% were male (mean age = 60
± 12.3 years). Duration of statin treatment prior to study was
6.9 ± 3.2 months. Baseline LDL prior to statin therapy was 3.8
± 0.71mmol/L. Interim ﬁndings showed that LDL was reduced
by 39 ± 14.2% with 84 ± 20% compliance measured as days
with correct dosing at month 3. Signiﬁcant linear relationship
was shown between LDL reduction and days with correct dosing
(R = 0.4848, p = 0.0015), dose count (R = 0.4535, p = 0.002)
but not timing of dose (R = 0.4959, p = 0.09). A 30% reduction
in serum LDL was corresponded to 80% compliance (days with
correct dosing). CONCLUSION: LDL reduction was correlated
with compliance to statin, and 30% LDL reduction appeared to
be achieved at 80% compliance with the prescribed statin
therapy.
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OBJECTIVE: To describe the patterns and predictors of adher-
ence with concomitant antihypertensive (AH) and lipid-lowering
(LL) therapies. METHODS: This retrospective cohort study
evaluated 8406 enrollees in a US managed care plan. Participants
initiated both AH and LL therapies within a 90-day period.
Adherence with AH and LL medications was measured at 3-
month intervals from the start of concomitant therapy for up to
36 months (mean follow-up 12.9 months). Patients were con-
sidered “adherent” with AH and LL therapies if they had ﬁlled
sufﬁcient prescriptions to cover at least 80% of days with both
classes of medications. A multivariate regression model evalu-
ated potential predictors of adherence with concomitant therapy,
including patient demographics, clinical characteristics, and
health service use patterns at baseline. RESULTS: Six months
after treatment initiation, only 36% of patients were adherent
with both AH and LL therapies, 35% did not adhere to either
regimen, and an additional 29% of patients were adherent with
either AH or LL therapy, but not both. These proportions
remained relatively steady over time. In the multivariate model,
age, gender, time since treatment began, and a history of coro-
nary heart disease or congestive heart failure were independently
associated with the likelihood of being adherent. The number of
other medications a patient was taking in the pretreatment year
was strongly and inversely associated with adherence to con-
comitant therapy. In addition, patients were more likely to be
adherent with concomitant therapy if they initiated AH and LL
therapy on or about the same date (within 0–30 days of each
other). CONCLUSIONS: Adherence with concomitant AH and
LL therapy is poor, with only 1 in 3 patients adherent to both
medications at 6 months. Initiating AH and LL therapy together
and keeping the number of other medications to a minimum may
improve adherence with concomitant therapy.
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OBJECTIVES: One study documented that physicians tend to
avoid giving prophylaxis to orthopedic patients taking aspirin
due to the concern of increased bleeding, though there is no clear
evidence from the literature. The aim of this study is to deter-
mine whether giving LMWH to patients taking aspirin increases
the hemorrhage risk compared with having only aspirin or
LMWH. This project will also demonstrate the use of the regres-
sion method in outcome research with a large administrative
database. METHODS: Diagnoses and procedures coded in ICD-
9-CM from 15 hospitals across the U.S. that include a mix of
hospital types and geographical locations. In the database, there
were 6847 orthopedic surgery patients who are given LMWH or
aspirin or both: 3680 undergoing hip replacement and 3167
undergoing knee replacement surgery. Logistic regression was
done to assess the bleeding risk. Independent variables included
are anticoagulants taking, procedure (hip/knee), length of stay
(LOS), age, gender, and comorbidities. SAS® for Windows® was
used in the statistical analysis. RESULTS: Combination use of
aspirin and LMWH results higher hemorrhage risk than aspirin
only (p < 0.0001). Combination use of aspirin and LMWH does
not result in different hemorrhage risk than LMWH only 
(p = 0.53). Hip replacement patients have a lower risk than knee
replacement patients. Patients with longer LOS and older
patients have a higher bleeding risk. There was no difference in
bleeding risk by sex. Comorbidities associated with a higher
bleeding risk included cardiovascular diseases, rheumatologic
disease, peptic ulcer, renal disease, malignancy, neurological dis-
orders, drug abuse, and depression. CONCLUSIONS: Based on
our ﬁndings, giving LMWHs to patients taking aspirin results in
more bleeding compared to aspirin alone. However, aspirin does
not inﬂuence the risk of bleeding due to LMWH signiﬁcantly so
patients taking aspirin can receive LMWH. Factors, such as 
age and comorbidities, should be considered before giving
thromboprophylaxis.
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OBJECTIVE: Cholesterol lowering has been shown to reduce
cardiovascular morbi-mortality. National and international (e.g,
US NCEP) guidelines have deﬁned LDL-C treatment initiation
levels (TIL) and goals for patients with different levels of coro-
nary heart disease (CHD) risk according to the number of CHD
risk factors (CRF) associated to dyslipidemia or to prior CHD.
The objective of this study was to measure the proportions 
of patients above AFSSAPS* TIL [1 CRF > 220mg/dl; 2 CRF >
190mg/dl; 3 CRFs > 160mg/dl; > 3 CRFs and prior CHD >
130mg/dl] and NCEP goal in patients with different CHD risk
level and treated with lipid lowering agents (LLA). METHOD:
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A total of 3173 dyslipidemic patients treated with LLA and
managed by general practitioners were randomly selected from
a French GPs computerized database. History of CHD and
number of CRF (age, family history of premature CHD,
smoking, hypertension, HDL-C < 0.9mmol/L, diabetes) were
documented. Percent of patients above AFSSAPS TIL and NCEP
goal was deﬁned for each level of CHD risk. RESULTS: Twenty-
one percent of patients had a history of CHD. Using AFSSAPS
guidelines the distribution of primary prevention patients
according to the number of CRFs (1, 2, 3, >3) was 1.6, 25.5,
31.7, and 20.1%, respectively. Almost 40% of CHD patients
remained above TIL and the percentages of primary prevention
patients above TIL varied from 3.9% for patients with 1 CRF
to 46.5% for patients with > 3 CRFs (p < 0.001). Using NCEP
guidelines, percentage of patients not at goal in the different
CHD risk categories were signiﬁcantly higher and 74.3% of
CHD patients were not at LDL-C treatment goal. CONCLU-
SION: Seventy-three percent of patients prescribed LLA were at
high CHD risk. Increasing with CHD risk level, large numbers
of patients were above TIL and LDL-C treatment goal. More
effective interventions are needed in lipid lowering therapy. *
AFSSAPS: French Drug Agency.
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OBJECTIVES: To examine the relationship between Interna-
tional Normalized Ratio (INR) and outcomes (major bleeding
events and strokes) in atrial ﬁbrillation (AF) patients on antico-
agulation with warfarin. METHODS: A systematic review and
meta-analysis of studies published in English between January 1,
1985 and October 30, 2002 was performed. MEDLINE
(PubMed), Current Contents, and relevant reference lists were
searched. Studies enrolling patients with nonvalvular AF on war-
farin anticoagulation were eligible for inclusion if they reported
stroke and/or major bleeding events in relation to INR, or time
spent in therapeutic range. The risk of bleeds in overanticoagu-
lated patients (INR > 3) and the risk of strokes in underantico-
agulated patients (INR < 2) was assessed. RESULTS: Twenty-one
studies (6,248 patients) met all inclusion criteria. Of the 21
studies, target conventional INR of 2 to 3 was used in 9. An INR
< 2, compared with an INR > 2, was associated with an odds
ratio (OR) for ischemic events of 5.07 (95% conﬁdence interval
(CI) = 2.92, 8.80). An INR > 3, compared with an INR < 3, was
associated with an OR for bleeding events of 3.21 (95% CI =
1.24, 8.28). On average, in the four studies with a target INR
range of 2 to 3, AF patients on warfarin spent 61% of time
within, 13% of time above and 26% below the therapeutic
range. CONCLUSION: Available evidence indicates that in
patients with non-valvular AF, the risk of ischemic stroke with
insufﬁcient warfarin anticoagulation (INR < 2), and the risk of
bleeding events with overanticoagulation (INR > 3) is signiﬁ-
cantly higher relative to AF patients maintained within the rec-
ommended INR of 2 to 3. However, the data are sparse,
heterogeneous, and mostly based on clinical trials. More studies
evaluating clinical outcomes in relation to INR are needed, espe-
cially in a real-world setting.
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OBJECTIVE: Evaluate treatment of hyperlipidemia in Latin
America and determine factors associated with NCEP-III LDL-
C goal attainment in Coronary Heart Disease (CHD)/CHD risk
equivalent (< = 100mg/dl) and non-CHD patients with 2+ risk
factor (< = 130mg/dl). METHODS: Retrospective observational
study at 40 randomly selected specialists and 20 general prac-
tices (GP) centers in Mexico, Brazil and Colombia. Physicians
randomly selected adult (age > = 18) patients prescribed lipid
lowering drug (LLD) for minimum 12 weeks. Date of ﬁrst LLD
was the index date; follow-up cholesterol measures and LLD pre-
scribed were evaluated for minimum 3 months after index date.
RESULTS: Three-hundred sixty patients were studied, 25% from
GP and 75% from specialist centers; 45% had CHD/CHD equiv-
alent, and 35% had 2+ risk factors. Mean age was 57yrs (SD
12) and 53% were male. Median LDL-C reduction required to
attain NCEP-III goal at baseline was 48% for CHD and 23%
for non-CHD patients. There was no signiﬁcant difference in
LDL-C reduction required at baseline among the three countries.
Initial LLD for CHD group were 27% low dose statins (sim-
vastatin 10mg or equipotent), 36% medium dose statins 
(simvastatin 20mg or equipotent) and 18% high dose statins
(simvastatin 40mg or equipotent). Proportion of physicians 
prescribing high dose statins was higher (p < 0.05) in Brazil
(26%) than Mexico (16%) and Colombia (15%). Overall 45%
patients treated with statins alone attained LDL-C goals; 
only 28% of CHD group. After controlling for age, gender,
country, initial LLD, titration and comorbidities, patients with
baseline LDL-C > = 190mg/dl (OR = 0.47; 95% CI 0.30–0.74),
hypertension (OR = 0.58; 95% CI 0.37–0.92) and CHD (OR =
0.38; 95% CI 0.24–0.60) were least likely to achieve LDL-C
goal. CONCLUSION: Hyperlipidemic patients in some Lati-
namerican countries are generally treated with statins alone;
majority (55%) of patients failed to reach recommended NCEP-
III LDL-C goals.
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OBJECTIVES: Clinical trials demonstrated that low-density
lipoprotein (LDL) lowering therapy reduces mortality and mor-
bidity in coronary heart disease patients. Therefore, it is impor-
tant to ensure patient adhering to their LDL-lowering therapies.
In July 2001, an intensive treatment protocol was introduced at
the United Christian Hospital (UCH) in Hong Kong. The
purpose of this study is to describe the impact of the protocol
on the lipid levels in patients having elective percutaneous coro-
nary interventions (PCI). METHODS: Case notes were reviewed
retrospectively. The study cohort consisted of patients who were
above 18 years old requiring ﬁrst elective PCI from 1 July 2000
to 30 June 2002. Patients with a history of previous PCI or 
coronary artery bypass surgery were excluded. The intensive
